Mer­ck KGaA: This time we’ve got our R&D act to­geth­er (se­ri­ous­ly)

Mer­ck KGaA has one of the worst R&D track records of any bio­phar­ma com­pa­ny of its size. Its life sci­ences group has gone well over a decade with­out any ma­jor new drug ap­provals. It’s ex­pe­ri­enced a se­ries of painful and of­ten pre­dictable set­backs in the clin­ic. And every time it’s promised rapid de­vel­op­ment progress in re­cent years, it’s had to back off the pledge.

But this time, the Ger­man com­pa­ny in­sists, they’ve got it down.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.